lotiglipron
Pfizer’s Embattled Obesity Program Loses Another GLP-1 Drug Due to Data and Competition Issues
Pfizer; obesity; GLP-1 agonist; clinical trial; liver injury; danuglipron; lotiglipron; PF-06954522; obesity drug development; competition
Actionable Insights Powered by AI
Pfizer; obesity; GLP-1 agonist; clinical trial; liver injury; danuglipron; lotiglipron; PF-06954522; obesity drug development; competition